Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.

European urology - 1 Oct 2008

Burger Maximilian, van der Aa Madelon N M, van Oers Johanna M M, Brinkmann Anke, van der Kwast Theodorus H, Steyerberg Ewout C, Stoehr Robert, Kirkels Wim J, Denzinger Stefan, Wild Peter J, Wieland Wolf F, Hofstaedter Ferdinand, Hartmann Arndt, Zwarthoff Ellen C

Abstract excerpt

OBJECTIVES: The clinical management of non-muscle-invasive urothelial cell carcinoma of the bladder (UCC) is challenging, as it has a marked tendency to recur and to progress. Aim of this study was to investigate the prognostic value of the WHO 1973 and 2004 grading systems and biomarkers FGFR3,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to FGFR3 gene

Share to Mutation

Share to Prognosis

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 18166262
DOI: 10.1016/j.eururo.2007.12.026

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18166262-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.PMID 18166262Read ↗

Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.Semantic proximity Read ↗

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Semantic proximity Read ↗

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.Semantic proximity Read ↗

FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.Semantic proximity Read ↗

Diagnostic and Prognostic Implications of FGFR3high/Ki67high Papillary Bladder Cancers.Semantic proximity Read ↗

FGFR3 Mutations in Urothelial Carcinoma: A Single-Center Study Using Next-Generation SequencingSemantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups.Semantic proximity Read ↗

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Semantic proximity Read ↗

Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of <i><scp>CDKN</scp>2A</i> deletions in the <i><scp>FGFR</scp>3</i> pathwaySemantic proximity Read ↗

Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.